DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $160

JP Morgan maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $172 to $160.

Benzinga · 02/28/2020 14:58

JP Morgan maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $172 to $160.